



Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Laser Treatment of Acne and Rosacea is addressed separately in medical policy 00162.

Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers laser treatment of onychomycosis to be **investigational**.*

Background/Overview

Onychomycosis (also known as dermatophytic onychomycosis or tinea unguium) is a fungal infection of the nail. Most toenail onychomycosis is caused by dermatophytes; however, many cases of fingernail onychomycosis are due to yeast. This condition may affect toenails or fingernails, although toenails are more likely to be infected. One or more of the toenails or fingernails may be involved, but seldom are all involved (Becker, 2013).

Onychomycosis is very common, accounting for half of all nail disorders, and is considered the most common nail disease in adults. Its incidence ranges from 2% to 13% in North America. It has been reported that 30% of individuals with a cutaneous fungal infection also have onychomycosis. Onychomycosis has been reported to occur in 2.6% of children (younger than 18 years of age), and in 90% of the elderly. Even with optimal diagnosis and treatment, 1 in 5 individuals with onychomycosis fail to achieve full clearance and cure with current topical and systemic therapies. The long-term recurrence rates of onychomycosis are relatively high, and range from 20% to 50% (de Moraes, 2013).

Risk factors that have been associated with onychomycosis include older age, swimming, tinea pedis, psoriasis, diabetes, immunodeficiency, genetic predisposition, and living with family members who have onychomycosis. Onychomycosis is usually asymptomatic. Individuals

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

frequently initially seek treatment for cosmetic reasons without any physical complaints. However, as the disease progresses, onychomycosis may interfere with wearing shoes, standing, walking, and exercising. In more severe cases, individuals may report paresthesia, pain, discomfort, and loss of dexterity. They may also report loss of self-esteem and lack of social interaction. Providers may suggest treating toenail onychomycosis in individuals with a history of ipsilateral lower extremity cellulitis and in individuals with diabetes who have additional risk factors for cellulitis (that is, prior cellulitis, venous insufficiency or edema) (Gupta, 2012, 2013).

Onychomycosis is frequently treated with either systemic or topical antifungal medications, or a combination of both systemic and topical medications. However, because the infection is embedded within the nail and is difficult to reach, full resolution of symptoms is slow and may take a year or more, since a new nail must grow and entirely replace the infected nail. Also, some of the medications used to treat onychomycosis are associated with serious adverse events, including hepatotoxicity (Gupta, 2012, 2013).

Researchers are currently investigating the use of various laser systems in the clinical setting as a relatively noninvasive treatment for onychomycosis. Laser therapy has the potential to be an ideal treatment option with respect to its ability to deliver a high concentration of energy to a relatively small area, limiting systemic side effects, while enhancing its ability to penetrate more deeply into the nail plate.

A number of Nd:YAG laser systems have been cleared by the FDA for marketing for the temporary increase of clear nail in individuals with onychomycosis. CO₂ laser systems have also been cleared by the FDA for fungal nail treatment. The regulatory 510K clearance of device systems by the FDA are made on the basis of "substantial equivalence" to the technical specifications of pre-existing devices already approved for marketing for onychomycosis, not on the basis of clinical trials data.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

Multiple randomized controlled trials (RCTs) have evaluated laser treatment for onychomycosis. Most RCTs have used neodymium-doped yttrium aluminum garnet (Nd:YAG) lasers; RCTs have also evaluated a near infrared diode laser (Landsman, 2010; Landsman 2012) and a carbon dioxide (CO₂) laser (Rajbanshi, 2020). In the trials, lasers were compared with no laser treatment (Hollmig, 2014; Kandpal, 2021; Karsai, 2017), sham treatment (Landsman 2010; Landsman 2012) and oral or topical antifungal treatment (Bonhert, 2018; Kim, 2016; Park, 2017; Xu, 2014). In the Zhang, 2012 RCT, all individuals underwent laser treatment, but duration of therapy varied. Several RCTs also included groups receiving a combination of laser and oral or topical treatment (Bonhert, 2018; Kim, 2016; Park, 2017; Xu, 2014). Sample sizes in the RCTs ranged from 20 to 128 individuals.

Findings of the trials were mixed. Several trials (Hollmig, 2014; Karsai, 2017; Sabbah, 2019) did not find statistically significant differences between the Nd:YAG laser treatment and comparison groups in their key efficacy outcomes. Other RCTs found significantly better results in groups receiving laser therapy compared with comparison interventions on at least some clinical outcomes.

Sabbah (2019) conducted a double-blind RCT comparing treatment with Nd:YAG 1064 nm short-pulse lasers and sham in 51 individuals with toenail onychomycosis. Individuals received treatments at 0, 12 and 24 weeks. The primary endpoint was the proportion of individuals with complete cure, defined as clear nail and negative mycology, at 52 weeks. The primary endpoint was achieved by none of the individuals in the laser group and 2 (7.7%) individuals in the sham group, $p=0.49$. Secondary endpoints also did not differ significantly between groups. For example, 24% of individuals in the laser group and 42% of individuals in the sham group had negative mycology at 52 weeks, $p=0.17$. In conclusion, the study demonstrated that laser was not effective in treating onychomycosis, with results actually trending in favor of placebo sham laser.

Bonhert (2018) did not find a significant difference between groups in the primary outcome, complete cure, but did find a significant benefit of laser therapy for the outcome, improvement in onychomycosis. The trial randomized 30 individuals with toenail onychomycosis to treatment with 48 weeks of daily topical antifungal solution or antifungal solution plus 6 sessions of a 1064 nm Nd:YAG laser spaced 4 weeks apart. Outcome evaluation was blinded and all participants completed the study. The primary outcome was complete cure at week 52, defined as negative mycological culture, negative potassium hydroxide (KOH) test and no nail onychomycosis. The primary outcome did not differ significantly between groups. At 52 weeks, there were no statistically significant differences between groups in mycological cure or KOH test results and thus the proportion of

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

individuals experiencing complete cure did not differ. Onychomycosis severity was assessed by a 30-point Scoring Clinical Index for Onychomycosis (SCIO Index). The laser group had significantly lower SCIO scores at weeks 36, 48 and 52 compared with the comparison group. Moreover, overall improvement rated by blinded investigators was significantly higher in the laser group at 48 and 52 weeks.

Combination therapy, lasers plus oral or topical antifungals, has also been studied in RCTs (Bunyaratavej, 2020; Khater, 2019; Kim, 2016; Park, 2017; Rajbanshi, 2020; Xu, 2014; Zhang, 2020). Most of these trials have found significant improvement in at least some clinical outcomes compared with oral or topical treatment alone. For example, Kim and colleagues (2016) compared 1064 nm Nd:YAG laser treatment, oral antifungal treatment and their combination in 56 individuals (217 nails). Blinding of outcome assessment was not discussed. The proportion of individuals who showed 'marked improvement' at 24 weeks in clinical response was 40.8% in the laser plus antifungal group, 31.6% in the laser-only group and 7.5% in the antifungal-only group. The difference in rates between each of the laser treatment groups and the antifungal-only group was statistically significant, $p < 0.05$. Moreover, the rate of complete response with mycological cure was 22.5% in the laser-plus-antifungal group and 15.2% in the laser-only group, which was significantly higher than the 4.5% rate in the antifungal-only group. Limitations of this study were that it only had 24 weeks of follow-up and it did not appear to be blinded.

In the study by Park and colleagues (2017), 128 individuals were randomized to 16 weeks of treatment with topical antifungal treatment alone ($n=64$) or topical treatment plus 1064 nm Nd:YAG laser treatment at 4 week intervals ($n=64$). The authors stated that outcome assessment was objective and independently assessed by two dermatologists. One of the primary efficacy outcomes, percent change in the lesion-free area over 16 weeks, did not differ significantly between groups. Change in the lesion-free area was 33.7% in the combined treatment group and 23% in the control group ($p=0.07$). However, there was a large and statistically significant difference between groups in another primary efficacy outcome, cumulative cure rate, defined as the achievement of clinically normal nail or negative mycology, with nail plate involvement of less than 10%. Cure rates were 72% in the combined treatment group and 20% in the topical treatment-only group, $p < 0.00001$.

However, a double-blind study by Bunyaratavej and colleagues (2020) did not find that Nd:YAG laser treatment of onychomycosis had superior outcomes to topical treatment alone or the combination of the two treatments. The study included 60 individuals, 20 per group. Individuals

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

assigned to laser treatment received 4 sessions, with a month between each session. After treatment, mycological cure rates were 35%, 60% and 65% in the laser, topical treatment and combination treatment groups, respectively. Rates in the topical and combination treatment groups were similar to one another and both were better than rates in the laser treatment group alone ($p=0.05$). Clinical cure rates were 10% in the laser group, 30% in the topical treatment group, and 30% in the combination treatment group; p-values for this analysis were not reported.

A 2019 meta-analysis of 24 prospective randomized and non-randomized trials evaluating laser treatment of onychomycosis (Yeung, 2019) found a pooled complete clinical cure rate of 7.2% (95% confidence interval [CI], 1.9-23.5%), clinical improvement rate of 67.2% (95% CI, 43.2-84.7%) and mycological cure rate of 70.4% (95% CI, 52.5-82.8%). The authors noted a high rate of heterogeneity among studies. The study did not report rates for any comparison intervention.

A 2022 meta-analysis of 12 RCTs compared the combination of laser treatment and topical antifungals with topical antifungals alone (Zhang, 2022). In pooled analyses, the authors found a significantly higher likelihood of clinical effectiveness (7 studies) (RR, 1.50, 95% CI, 1.24 to 1.83) and mycological cure (6 studies) (RR, 1.27, 95% CI, 1.10 to 1.48) in the group receiving the laser and topical antifungal treatment compared with antifungals alone. Only 2 studies addressed the complete cure rate. In their assessment of risk of bias, the authors noted that only 1 of 12 RCTs mentioned blinding of participants and personnel and only 3 of the 12 RCTs stated that outcome evaluation was blinded. The length of intervention and length of follow-up varied among studies.

A 2021 systematic review of literature on lasers for treating dermatophyte onychomycosis (Gupta, 2021) included clinical studies of laser monotherapy that evaluated the great toenail as the target nail, reported mycological confirmation of onychomycosis and included a clear definition of efficacy. A total of nine studies met the review's inclusion criteria. Outcome measures and definitions of efficacy varied among studies. Clinical cure defined as 100% clear nail was reported in one study and clinical cure defined as less than 10% clinical involvement was reported in four studies. Mycological cure defined as both negative microscopy and negative fungal culture was reported in two studies, mycological cure defined as negative microscopy only was evaluated in three studies, and mycological cure defined as negative fungal culture only was reported in five studies. The authors did not pool study results.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

The British Association of Dermatologists' 2014 guideline on treatment of onychomycosis stated that "newer devices" including Nd:YAG lasers showed "promising results" but recommendations could not be made regarding their use at the time. No guideline updates were available.

In summary, a number of RCTs have evaluated laser treatment for onychomycosis. Study findings were mixed, as were the design quality of the trials; for example, not all studies had blinded assessment of outcomes. Study outcome measures were often of unclear clinical significance (e.g. percent change in lesion-free area or "marked improvement"), and did not include evaluation of outcomes considered to be complications of onychomycosis (e.g. soft tissue bacterial infection, pain; or even quality of life). Furthermore, only one study had at least 1 year of follow-up. Length of follow-up may not have been long enough to adequately determine cure rate or to assess rates of recurrence. Finally, the mechanisms of action and the optimal regimen for laser therapy, e.g. number and frequency of treatments, remain unclear. Additional data are needed before conclusions can be drawn about the durable, clinically meaningful efficacy of lasers for treating onychomycosis.

Supplemental Information/Definitions

Dermatophytes: Fungi that require keratin to grow that cause superficial fungal infections on the nails, hair and skin.

Laser: The word is an acronym for "light amplification by the stimulated emission of radiation." Lasers are devices that emit amplified, single-color light.

Onychomycosis: Fungal infection of the nail.

References

Peer Reviewed Publications:

1. Becker C, Bershow A. Lasers and photodynamic therapy in the treatment of onychomycosis: a review of the literature. *Dermatol Online J.* 2013; 19(9):19611.
2. Bonhert K, Dorizas A, Sadick NS. Efficacy of combination therapy with efinaconazole 10% solution and 1064 nm Nd:YAG laser for treatment of toenail onychomycosis. *J Cosmet Laser Ther.* 2018:1-5.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

3. Bunyaratavej S, Wanitphakdeedecha R, Ungakornpairote C, et al. Randomized controlled trial comparing long-pulsed 1064-Nm neodymium: Yttrium-aluminum-garnet laser alone, topical amorolfine nail lacquer alone, and a combination for nondermatophyte onychomycosis treatment. *J Cosmet Dermatol*. 2020; 19(9):2333-2338.
4. de Morais OO, Costa IM, Gomes CM, et al. The use of the Er:YAG 2940nm laser associated with amorolfine lacquer in the treatment of onychomycosis. *An Bras Dermatol*. 2013; 88(5):847-849.
5. Durme DJ. Ch 4 Disease of the skin. In: Bope & Kellerman: Conn's Current Therapy 2013, 1st ed. Saunders. St. Louis, MO. 2012; 242-244.
6. El-Tatawy RA, Abd El-Naby NM, El-Hawary EE, Talaat RA. A comparative clinical and mycological study of Nd-YAG laser versus topical terbinafine in the treatment of onychomycosis. *J Dermatolog Treat*. 2015; 26(5):461-464.
7. Gupta AK, Simpson FC. Laser therapy for onychomycosis. *J Cutan Med Surg*. 2013; 17(5):301-307.
8. Gupta AK, Simpson F. Newly approved laser systems for onychomycosis. *J Am Podiatr Med Assoc*. 2012; 102(5):428-430.
9. Gupta AK, Venkataraman M, Quinlan EM. Efficacy of lasers for the management of dermatophyte toenail onychomycosis. *J Am Podiatr Med Assoc*. 2022;112(1):20-236.
10. Gupta AK, Versteeg SG. A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. *J Eur Acad Dermatol Venereol*. 2017; 31(7):1111-1118.
11. Hamed Khater M, Khattab FM. Combined long-pulsed Nd-Yag laser and itraconazole versus itraconazole alone in the treatment of onychomycosis nails. *J Dermatolog Treat*. 2019; 31(4):401-409.
12. Hochman LG. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. *J Cosmet Laser Ther*. 2011; 13(1):2-5.
13. Hollmig ST, Rahman Z, Henderson MT, et al. Lack of efficacy with 1064-nm neodymium:yttrium-aluminum-garnet laser for the treatment of onychomycosis: a randomized, controlled trial. *J Am Acad Dermatol*. 2014; 70(5):911-917.
14. Hoy NY, Leung AK, Metelitsa AI, Adams S. New concepts in median nail dystrophy, onychomycosis, and hand, foot, and mouth disease nail pathology. *ISRN Dermatol*. 2012; 2012:680163.
15. Kandpal R, Arora S, Arora D. A study of Q-switched Nd:YAG laser versus itraconazole in management of onychomycosis. *J Cutan Aesthet Surg*. 2021; 14(1):93-100.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

16. Karsai S, Jager M, Oesterhelt A, et al. Treating onychomycosis with the short-pulsed 1064-nm-Nd:YAG laser: results of a prospective randomized controlled trial. *J Eur Acad Dermatol Venereol*. 2017; 31(1):175-180.
17. Kim TI, Shin MK, Jeong KH, et al. A randomized comparative study of 1064 nm Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser and topical antifungal treatment of onychomycosis. *Mycoses*. 2016; 59 (12):803-810.
18. Landsman AS, Robbins AH. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure: some follow-up observations at 270 days. *J Am Podiatr Med Assoc*. 2012; 102(2):169-171.
19. Landsman AS, Robbins AH, Angelini PF, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. *J Am Podiatr Med Assoc*. 2010; 100(3):166-177.
20. Park KY, Suh JH, Kim BJ, et al. Randomized clinical trial to evaluate the efficacy and safety of combination therapy with short-pulsed 1,064-nm Neodymium-doped yttrium aluminium garnet laser and amorolfine nail lacquer for onychomycosis. *Ann Dermatol*. 2017; 29(6):699-705.
21. Rajbanshi B, Shen L, Jiang M et al. Comparative study of traditional ablative CO₂ laser-assisted topical antifungal with only topical antifungal for treating onychomycosis: A multicenter study. *Clin Drug Investig*. 2020; 40(6):575-582.
22. Sabbah L, Gagnon C, Bernier FE, Maari C. A randomized, double-blind, controlled trial evaluating the efficacy of Nd:YAG 1064 nm short-pulse laser compared with placebo in the treatment of toenail onychomycosis. *J Cutan Med Surg*. 2019; 23(5):507-512.
23. Xu Y, Miao X, Zhou B, Luo D. Combined oral terbinafine and long-pulsed 1,064-nm Nd: YAG laser treatment is more effective for onychomycosis than either treatment alone. *Dermatol Surg*. 2014; 40(11):1201-1207.
24. Yeung K, Ortnr VK, Martinussen T, et al. Efficacy of laser treatment for onychomycotic nails: a systematic review and meta-analysis of prospective clinical trials. *Lasers Med Sci*. 2019; 34 (8):1513-1525. .
25. Zhang J, Lin P, Li J et al.Efficacy of laser therapy combined with topical antifungal agents for onychomycosis: a systematic review and meta-analysis of randomised controlled trials. *Lasers Med Sci*. 2022; 37(6):2557-2569.
26. Zhang R, Wang D, Zhuo F, et al. Long-pulse Nd: YAG 1064-nm laser treatment for onychomycosis. *Chin Med J (Engl)*. 2012; 125(18):3288-3291.
27. Zhang J, Zhang Y, Qin J, et al. Comparison of a fractional 2940-nm Er:YAG laser and 5% amorolfine lacquer combination therapy versus a 5% amorolfine lacquer monotherapy for the

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

treatment of onychomycosis: a randomized controlled trial. Lasers Med Sci. 2021; 36(1):147-152.

Government Agency, Medical Society, and Other Authoritative Publications:

1. Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists' guidelines for the management of onychomycosis. 2014. Br J Dermatol. 2014; 171(5):937-958.

Websites for Additional Information:

1. Centers for Disease Control (CDC). Fungal nail infection. Available at: <https://www.cdc.gov/fungal/nail-infections.html>.
2. American Academy of Dermatology (AAD). Nail fungus. Available at: <https://www.aad.org/public/diseases/contagious-skin-diseases/nail-fungus>.

Policy History

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

06/27/2013	Medical Policy Committee review
07/17/2013	Medical Policy Implementation Committee approval.
07/10/2014	Medical Policy Committee review
07/16/2014	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/06/2015	Medical Policy Committee review
08/19/2015	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/04/2016	Medical Policy Committee review
08/17/2016	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
08/03/2017	Medical Policy Committee review
08/23/2017	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/09/2018	Medical Policy Committee review

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

08/15/2018	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/01/2019	Medical Policy Committee review
08/14/2019	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/19/2019	Coding update
08/06/2020	Medical Policy Committee review
08/12/2020	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/05/2021	Medical Policy Committee review
08/11/2021	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/04/2022	Medical Policy Committee review
08/10/2022	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/03/2023	Medical Policy Committee review
08/09/2023	Medical Policy Implementation Committee approval. Extensive policy revisions. Coverage eligibility unchanged.

Next Scheduled Review Date: 08/2024

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)†, copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT,

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	17999, 96999
HCPCS	No codes
ICD-10 Diagnosis	B35.1, L60.0-L60.9

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Laser Treatment of Onychomycosis

Policy # 00371

Original Effective Date: 07/17/2013

Current Effective Date: 09/11/2023

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.